trending Market Intelligence /marketintelligence/en/news-insights/trending/WIRX2WDCM-g6a7LDBIqV6A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Applied Genetic's gene therapy for eye disease gets US FDA orphan designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Applied Genetic's gene therapy for eye disease gets US FDA orphan designation

The U.S. Food and Drug Administration granted orphan drug designation for Applied Genetic Technologies Corp.'s gene therapy product candidate to treat X-linked retinitis pigmentosa caused by mutations in the RPGR gene.

X-linked retinitis pigmentosa is an inherited condition that causes progressive vision loss, beginning with night blindness in young boys followed by progressive constriction of the field of vision.

In June 2016, the European Commission granted the product an orphan designation for the same indication.

Applied Genetic Technologies has also been granted orphan drug designation from the FDA and European Commission for its gene therapy product candidates to treat X-linked retinoschisis and achromatopsia caused by mutations in the CNGA3 and CNGB3 genes.